CAPS Medical News
6 articles
/PRNewswire/ -- CAPS Medical, a clinical-stage MedTech company developing a platform for selective tumor ablation across multiple indications, today announced...
CAPS Medical, a clinical-stage MedTech company, has received Breakthrough Device Designation from the FDA for its PlasmaSure™ System, aimed at treating non-muscle invasive bladder cancer (NMIBC). This designation supports the companys mission to transform tumor ablation into a simple, in-office procedure. The PlasmaSure™ platform uses non-thermal atmospheric plasma energy for selective tumor ablation, preserving healthy tissue. CAPS Medical has completed a first-in-human clinical study with promising results and is preparing for pivotal trials and U.S. market entry. The company is also expanding its technology to other cancer indications and establishing a U.S. headquarters to support its growth phase.
Product StageFDA approved/pending approvalExpand
"בדרך למהפך בטיפול בגידולים סרטניים" - Forbes Israel
CAPS Medical גייסה 3.5 מיליון דולר לניסוי הקליני הראשון שלה
CAPS Medical, a company developing a new method for cancer growth removal, has raised $3.5 million for its first clinical trial. The company was founded within the MEDX Xelerator incubator, established by medical device entrepreneur Harel Gadot. The investors in this round were Chasing Value Asset Management, Israel Investment Fund Group, XACT Robotics, and the Technions venture capital fund. CAPS uses cold plasma to treat cancer, a technology that has shown promise in selectively killing cancer cells. The companys system minimizes the exposure of healthy cells to plasma, allowing for more targeted and selective treatment with fewer side effects. CAPS was developed in collaboration with the Technion and Rambam Hospital.
Investment
CAPS Medical Completes $3.5 Million Series A Round for Selective Cancer Treatment Technology
CAPS Medical, a developer of a non-thermal plasma device for cancer treatment, has announced the completion of a $3.5 million Series A financing round. The funding will support the companys first clinical trial and further development of its portfolio for treating solid tumors. CAPS Medical aims to achieve regulatory clearance in the U.S. market based on the results of these studies. The financing round was led by Chasing Value Asset Management and the Israel Investment Fund Group, with participation from other investors including the Technion Research and Development Foundation and XACT Robotics. The companys platform uses non-thermal plasma to selectively target and kill cancer cells without damaging healthy tissue, offering a more precise and less harmful treatment option.
Investment
New plasma cancer treatment kills malignant cells
CAPS Medical, a small startup based in Or Yehuda, Israel, has developed a disposable catheter that delivers cold atmospheric plasma (CAP) to treat non-muscle invasive bladder cancer (NMIBC). CAPS Medicals technology allows CAP to reach deep into the body, causing cancer cell death and triggering an immune response that targets additional cancer cells. The company plans to expand its technology to other types of solid organ tumors. CAPS Medical is currently in the prototype stage and aims to develop a clinical-grade system for testing on humans. The company has received support from the MEDX technology accelerator and has won awards for its innovation. It is backed by investors such as Boston Scientific, Intellectual Ventures, MEDX Ventures, and Sheba Medical Center.
Customers
https://www.jpost.com/health-science/israeli-startup-creates-new-tech-to-target-internal-solid-tumors-614397
